Seeking Alpha

Wall Street Titan

View Wall Street Titan's Comments BY TICKER:
  • Upcoming Data For Athersys Crucial, But Not In Terms Of Immediate Share Price [View article]
    One interesting factor regarding UC preclinical data that some may fail to appreciate or take for granted is that the same HUMAN version of Multistem in this Phase II trail was used in preclinical research to treat mice. Think about that for a minute. When I first heard this I was blown away. One would have thought that Athersys would have created a murine version of Multistem. Who would think that a large number of human cells could enter the bloodstream of a mouse and not kill the subject with an immune reaction, nonetheless CURE the disease. I know that Gil VanBokkelen thought it silly to try and use multi-stem in a different species and even wagered one of his scientists that it would kill the mouse. That is one of the reasons I feel good about this trial. The human multistem worked in a different species. That's remarkable and, in my view, the odds are pretty good it will work in humans. After all, the MAPCs are the results of billions of years of evolution as opposed to a man made compound that will usually has side effects to at lease some sub-sector of the population. See more here: http://bit.ly/1hxXg1Q
    Apr 7 04:44 PM | 11 Likes Like |Link to Comment
  • Upcoming Data For Athersys Crucial, But Not In Terms Of Immediate Share Price [View article]
    Solid results form Multi-Stem in this Phase II trial for UC IS a big deal and there is no reason to believe that eight weeks is too short of a time frame to start seeing signs of efficacy. The fact that MultiStem is platform of potential therapies, the biggest being a treatment for stroke, means that any good data gets extrapolated to the value of the platform. You can bet that the smart management teams at Athersys and Pfizer know what they are doing to build value. They would not be releasing 8 week data if pre clinical work in animals didn't support the thesis that 8 weeks is sufficient to show something important. Not sure of your basis for believing otherwise.
    Apr 7 02:29 PM | 11 Likes Like |Link to Comment
  • Athersys: Two Crucial Near-Term Events [View article]
    Clarification from the map3.com website: "Map3 is a cellular allogeneic bone graft comprised of demineralized bone powder, mineralized cancellous bone chips and viable stem cells from a single cadaveric donor. Map3 provides the three elements necessary for bone repair in a single allograft."

    The difference between MAPCs and Multistem is that MultiStem is cultured into multiple doses. MAPCs are the cells as extracted but not multiplied. They are both normally used allogeneicly (but I suppose the could be used autogolously) but since MAPCs are NOT more than minimally manipulated, they do not need FDA approval for homologous as being used by RTI Biologics.
    Mar 25 10:58 AM | Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Lou,

    "My basic point is this, and I will reiterate it. Athersys, fundamentally, rises or falls based on Multistem. Other revenue streams are insignificant and will not be able to stem the company's losses."

    You're not saying anything. EVERYONE KNOWS this.


    "If MultiStem succeeds, their reasoning will be correct in retrospect. If it fails, it will be incorrect. But that is long term, not mid or short term."

    They have two Phase II results due within the year. UC within a couple of months. What are you talking about?


    "Anyone else can site whatever evidence you think proves your own convictions.

    That statement tells me you spent no time looking at the evidence because you provided none of your own.


    "But when it comes down to it, the pool of buyers for Athersys is thin."

    Then how do you explain the big ramp up in institutional ownership in the last few months?

    It is clear that you put out this article without doing much DD. What is more troubling is, that even when given the opportunity to debate, you still fail to your DD and just speak in generalities. I give up.
    Mar 6 12:41 PM | 4 Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    It is very clear that you are toosmarttoarguewith. Have you considered sharing your vast KNOWledge about everything by authoring your own SA article on ACTC? We'd all love to read it and would enjoy commenting on it.
    Mar 5 10:50 PM | 4 Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Based upon what we've heard on the conference calls, there seems to be serious discussions going on between Athersys and the appropriate officials in Japan. My guess would be 2015.
    Mar 5 08:15 AM | Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Lou, any intelligent counterpoints you'd like to share or have you come to reevaluate your position on Athersys?
    Mar 4 10:57 PM | 6 Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    lou? Lou?, LOU? Is anybody home? I've tried to engage you several times in an intelligent discussion to no avail. This article solidifies the point I have tried to get your feedback on... http://on.mktw.net/1kP...
    Mar 3 03:57 PM | Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Lou, how did your analysis of the new Japan regenerative law contribute to the theme of your article that claims there is no reason for the recent appreciation in ATHX shares? More specifically, how much weight did you give to the new law and what it might mean to short term revenue opportunities for the company?
    Mar 3 10:20 AM | 5 Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Sumi..... good point.
    Feb 27 09:16 AM | 1 Like Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    MoneyGrubber13, I was going to ask the same question. MAPCs, as all the educated commentators on this article KNOW, are not altered. They are the natural miracle of human evolution. When someone considers himself "too smart" it often leaves him unable to accept or comprehend what he does not know. Geron was the first mover in embryonic stem cell therapies and once had the biggest market cap of the stem cell sector. They abandoned their pursuit of embryonic stem cell therapies and are now out of the stem cell business. WHY?

    BTW, it is really impressive to see so many ATHX shareholders that have really spent a great deal of time doing their due diligence on this company and not only have a deep understanding of the potential new paradigm in medicine that Athersys may represent but also understand the risks.
    Feb 26 11:07 PM | 1 Like Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Lou take the challenge posed by commenters. Write a new article that backs up your arguments against this long comment list, point by point, and back up your assertions with COLD HARD FACTS that include links. Start off by explaining why you chose to completely ignore the new regenerative medicine laws in Japan: http://seekingalpha.co... If this were a moot court with an impartial judge you'd be getting your you know what kicked.
    Feb 26 08:02 AM | 6 Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Lou, name ONE study that shows that MPCs are better than MAPCs in ant attribute. Just name ONE and support it with quality data please. You will not be able to.
    Feb 26 07:51 AM | 6 Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Sumi, I didn't even notice that he got his cells reversed. Louis, I think you will be buying shares after you become just a bit more educated about the company's technology.
    Feb 25 04:50 PM | 12 Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Louis. Thanks for your article. As one of the Athersys authors you linked to I have a pretty deep understanding of the company. What I find interesting that you really seemed to struggle to make your case that the runup is shares was unwarranted. Your paragraph below designates this article as one of the most bullish BEAR articles written on Athersys:

    "In addition, the company is generating revenue (which is more than can be said for a lot of development stage biotechnology companies), has a strong management team, is well financed and has a product that looks to be performing well at the cutting edge of an industry that could change the face of modern medicine."

    I think you need to take another look at the advantages of MAPCs over The Mesoblast cell. You linked to what was apparently a very early article on MAPCs. The big advantage of MAPCs is the ability to produce millions of doses from a single donor without a drop in efficacy. No other cell in Phase II clinical trials can make this claim, a claim that is supported by published research: http://bit.ly/1eQqc9Q
    Feb 25 04:28 PM | 25 Likes Like |Link to Comment
More on ATHX by Wall Street Titan
COMMENTS STATS
248 Comments
398 Likes